Cover Image
市場調查報告書

肝癌:開發平台分析

Liver Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 337045
出版日期 內容資訊 英文 1171 Pages
訂單完成後即時交付
價格
Back to Top
肝癌:開發平台分析 Liver Cancer - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 1171 Pages
簡介

肝癌是在肝臟發生的癌症。危險因素為,肝炎、肝硬化、肝臟的疤痕化,男性,出生時的體重輕等。症候有右腹部腫塊或疼痛、皮膚發黃。治療有化療、放射治療、手術等。

本報告提供肝癌的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

  • 簡介
  • 肝癌 概要
  • 治療藥的開發
  • 企業開發中的治療藥
  • 大學/機關研究中的治療藥
  • 開發中產品概況
  • 企業開發中的產品
  • 大學/機關研究中的產品
  • 開發治療藥的企業
  • 治療藥的評估
  • 藥物簡介
  • 最近的開發平台趨勢
  • 暫停中的計劃
  • 開發中止的產品
  • 產品開發的里程碑
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8854IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.

Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.

Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Liver Cancer Overview
  • Therapeutics Development
  • Liver Cancer - Therapeutics under Development by Companies
  • Liver Cancer - Therapeutics under Investigation by Universities/Institutes
  • Liver Cancer - Pipeline Products Glance
  • Liver Cancer - Products under Development by Companies
  • Liver Cancer - Products under Investigation by Universities/Institutes
  • Liver Cancer - Companies Involved in Therapeutics Development
  • Liver Cancer - Therapeutics Assessment
  • Drug Profiles
  • Liver Cancer - Dormant Projects
  • Liver Cancer - Discontinued Products
  • Liver Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Liver Cancer, H2 2016
  • Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Liver Cancer - Pipeline by 4SC AG, H2 2016
  • Liver Cancer - Pipeline by AB Science SA, H2 2016
  • Liver Cancer - Pipeline by Acceleron Pharma Inc, H2 2016
  • Liver Cancer - Pipeline by ACROVIS Pharma AG, H2 2016
  • Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Liver Cancer - Pipeline by Aduro BioTech Inc, H2 2016
  • Liver Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Liver Cancer - Pipeline by Alfact Innovation, H2 2016
  • Liver Cancer - Pipeline by Alissa Pharma, H2 2016
  • Liver Cancer - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
  • Liver Cancer - Pipeline by Amgen Inc, H2 2016
  • Liver Cancer - Pipeline by AndroScience Corp, H2 2016
  • Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H2 2016
  • Liver Cancer - Pipeline by ArQule Inc, H2 2016
  • Liver Cancer - Pipeline by Array BioPharma Inc, H2 2016
  • Liver Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Liver Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Liver Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Bayer AG, H2 2016
  • Liver Cancer - Pipeline by BeiGene Ltd, H2 2016
  • Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Liver Cancer - Pipeline by BioCancell Ltd, H2 2016
  • Liver Cancer - Pipeline by Biogazelle NV, H2 2016
  • Liver Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Bioneer Corp, H2 2016
  • Liver Cancer - Pipeline by BioStar Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by BLR Bio LLC, H2 2016
  • Liver Cancer - Pipeline by Blueprint Medicines Corp, H2 2016
  • Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Liver Cancer - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Boston Biomedical Inc, H2 2016
  • Liver Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Liver Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016
  • Liver Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016
  • Liver Cancer - Pipeline by Celgene Corp, H2 2016
  • Liver Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Celprogen Inc, H2 2016
  • Liver Cancer - Pipeline by Celsion Corp, H2 2016
  • Liver Cancer - Pipeline by China Medical System Holdings Ltd, H2 2016
  • Liver Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
  • Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Liver Cancer - Pipeline by Chroma Therapeutics Ltd, H2 2016
  • Liver Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Liver Cancer - Pipeline by CohBar Inc, H2 2016
  • Liver Cancer - Pipeline by CZ BioMed Corp, H2 2016
  • Liver Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Liver Cancer - Pipeline by Delcath Systems Inc, H2 2016
  • Liver Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
  • Liver Cancer - Pipeline by Eisai Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Liver Cancer - Pipeline by Endocyte Inc, H2 2016
  • Liver Cancer - Pipeline by Epeius Biotechnologies Corp, H2 2016
  • Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H2 2016
  • Liver Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Exelixis Inc, H2 2016
  • Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Liver Cancer - Pipeline by Faron Pharmaceuticals Oy, H2 2016
  • Liver Cancer - Pipeline by Formosa Laboratories Inc, H2 2016
  • Liver Cancer - Pipeline by Galaxy Biotech LLC, H2 2016
  • Liver Cancer - Pipeline by Genelux Corp, H2 2016
  • Liver Cancer - Pipeline by Genoscience Pharma, H2 2016
  • Liver Cancer - Pipeline by Genosco Inc, H2 2016
  • Liver Cancer - Pipeline by Gilead Sciences Inc, H2 2016
  • Liver Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Liver Cancer - Pipeline by Golden Biotechnology Corp, H2 2016
  • Liver Cancer - Pipeline by Green Cross Cell Corp, H2 2016
  • Liver Cancer - Pipeline by Green Cross Corp, H2 2016
  • Liver Cancer - Pipeline by H3 Biomedicine Inc, H2 2016
  • Liver Cancer - Pipeline by HanAll Biopharma Co Ltd, H2 2016
  • Liver Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016
  • Liver Cancer - Pipeline by HitGen LTD, H2 2016
  • Liver Cancer - Pipeline by Horizon Pharma Plc, H2 2016
  • Liver Cancer - Pipeline by Immune Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Immunicum AB, H2 2016
  • Liver Cancer - Pipeline by Immunitor Inc, H2 2016
  • Liver Cancer - Pipeline by Immunomedics Inc, H2 2016
  • Liver Cancer - Pipeline by Immunophotonics Inc, H2 2016
  • Liver Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016
  • Liver Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by In-Cell-Art SAS, H2 2016
  • Liver Cancer - Pipeline by Incanthera Ltd, H2 2016
  • Liver Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Inspyr Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by InteRNA Technologies BV, H2 2016
  • Liver Cancer - Pipeline by Intezyne Technologies Inc, H2 2016
  • Liver Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
  • Liver Cancer - Pipeline by Jenrin Discovery Inc, H2 2016
  • Liver Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Liver Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016
  • Liver Cancer - Pipeline by KAHR medical Ltd, H2 2016
  • Liver Cancer - Pipeline by Karcinolys SAS, H2 2016
  • Liver Cancer - Pipeline by Keystone Nano Inc, H2 2016
  • Liver Cancer - Pipeline by Kite Pharma Inc, H2 2016
  • Liver Cancer - Pipeline by Komipharm International Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Kowa Company Ltd, H2 2016
  • Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Liver Cancer - Pipeline by Lidds AB, H2 2016
  • Liver Cancer - Pipeline by Ligand Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
  • Liver Cancer - Pipeline by Lytix Biopharma AS, H2 2016
  • Liver Cancer - Pipeline by MaxCyte Inc, H2 2016
  • Liver Cancer - Pipeline by MedImmune LLC, H2 2016
  • Liver Cancer - Pipeline by Medivation Inc, H2 2016
  • Liver Cancer - Pipeline by Medivir AB, H2 2016
  • Liver Cancer - Pipeline by Merck & Co Inc, H2 2016
  • Liver Cancer - Pipeline by Merck KGaA, H2 2016
  • Liver Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Midatech Pharma Plc, H2 2016
  • Liver Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Mina Therapeutics Ltd, H2 2016
  • Liver Cancer - Pipeline by Molecular Partners AG, H2 2016
  • Liver Cancer - Pipeline by MultiCell Technologies Inc, H2 2016
  • Liver Cancer - Pipeline by NormOxys Inc, H2 2016
  • Liver Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Novartis AG, H2 2016
  • Liver Cancer - Pipeline by NovaTarg Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Nymox Pharmaceutical Corp, H2 2016
  • Liver Cancer - Pipeline by Omeros Corp, H2 2016
  • Liver Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
  • Liver Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by OncoTherapy Science Inc, H2 2016
  • Liver Cancer - Pipeline by Oneness Biotech Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Onxeo SA, H2 2016
  • Liver Cancer - Pipeline by OPKO Health Inc, H2 2016
  • Liver Cancer - Pipeline by Oribase Pharma, H2 2016
  • Liver Cancer - Pipeline by OSE Immunotherapeutics, H2 2016
  • Liver Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Peptinov SAS, H2 2016
  • Liver Cancer - Pipeline by PepVax Inc, H2 2016
  • Liver Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Pfizer Inc, H2 2016
  • Liver Cancer - Pipeline by Pharma Mar SA, H2 2016
  • Liver Cancer - Pipeline by PharmAbcine Inc, H2 2016
  • Liver Cancer - Pipeline by PharmaEssentia Corp, H2 2016
  • Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2016
  • Liver Cancer - Pipeline by ProMetic Life Sciences Inc, H2 2016
  • Liver Cancer - Pipeline by Provecs Medical GmbH, H2 2016
  • Liver Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by RedHill Biopharma Ltd, H2 2016
  • Liver Cancer - Pipeline by Regen BioPharma Inc, H2 2016
  • Liver Cancer - Pipeline by Regulus Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Rigontec GmbH, H2 2016
  • Liver Cancer - Pipeline by Samumed LLC, H2 2016
  • Liver Cancer - Pipeline by Saronic Biotechnology Inc, H2 2016
  • Liver Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2016
  • Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2016
  • Liver Cancer - Pipeline by Silence Therapeutics Plc, H2 2016
  • Liver Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016
  • Liver Cancer - Pipeline by Somantix BV, H2 2016
  • Liver Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Synovo GmbH, H2 2016
  • Liver Cancer - Pipeline by TaiRx Inc, H2 2016
  • Liver Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016
  • Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Liver Cancer - Pipeline by Targetome SA, H2 2016
  • Liver Cancer - Pipeline by TC BioPharm Ltd, H2 2016
  • Liver Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
  • Liver Cancer - Pipeline by Therapure Biopharma Inc, H2 2016
  • Liver Cancer - Pipeline by Theravectys SA, H2 2016
  • Liver Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2016
  • Liver Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Liver Cancer - Pipeline by Transgene Biotek Ltd, H2 2016
  • Liver Cancer - Pipeline by Tumorend LLC, H2 2016
  • Liver Cancer - Pipeline by UbiVac LLC, H2 2016
  • Liver Cancer - Pipeline by VasGene Therapeutics Inc, H2 2016
  • Liver Cancer - Pipeline by Vaxon Biotech, H2 2016
  • Liver Cancer - Pipeline by Vect-Horus SAS, H2 2016
  • Liver Cancer - Pipeline by Verlyx Pharma Inc, H2 2016
  • Liver Cancer - Pipeline by VG Life Sciences Inc, H2 2016
  • Liver Cancer - Pipeline by Vicus Therapeutics LLC, H2 2016
  • Liver Cancer - Pipeline by Virttu Biologics Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Liver Cancer - Dormant Projects, H2 2016
  • Liver Cancer - Dormant Projects (Contd..1), H2 2016
  • Liver Cancer - Dormant Projects (Contd..2), H2 2016
  • Liver Cancer - Dormant Projects (Contd..3), H2 2016
  • Liver Cancer - Dormant Projects (Contd..4), H2 2016
  • Liver Cancer - Dormant Projects (Contd..5), H2 2016
  • Liver Cancer - Dormant Projects (Contd..6), H2 2016
  • Liver Cancer - Dormant Projects (Contd..7), H2 2016
  • Liver Cancer - Dormant Projects (Contd..8), H2 2016
  • Liver Cancer - Dormant Projects (Contd..9), H2 2016
  • Liver Cancer - Dormant Projects (Contd..10), H2 2016
  • Liver Cancer - Dormant Projects (Contd..11), H2 2016
  • Liver Cancer - Dormant Projects (Contd..12), H2 2016
  • Liver Cancer - Dormant Projects (Contd..13), H2 2016
  • Liver Cancer - Dormant Projects (Contd..14), H2 2016
  • Liver Cancer - Dormant Projects (Contd..15), H2 2016
  • Liver Cancer - Dormant Projects (Contd..16), H2 2016
  • Liver Cancer - Dormant Projects (Contd..17), H2 2016
  • Liver Cancer - Dormant Projects (Contd..18), H2 2016
  • Liver Cancer - Dormant Projects (Contd..19), H2 2016
  • Liver Cancer - Discontinued Products, H2 2016
  • Liver Cancer - Discontinued Products (Contd..1), H2 2016
  • Liver Cancer - Discontinued Products (Contd..2), H2 2016
  • Liver Cancer - Discontinued Products (Contd..3), H2 2016

List of Figures

  • Number of Products under Development for Liver Cancer, H2 2016
  • Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top